Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

PharmAsia News Notable Notes: India’s Sun, Dishman Price Targets Raised By Citigroup, Dr Reddy’s Maintained As Hold

This article was originally published in PharmAsia News

Executive Summary

NEW DELHI - Following fourth quarter earnings, Citigroup Global Markets hiked the price target for India's Sun and Dishman pharmaceutical companies citing strong and robust guidance and maintained a hold rating on Dr Reddy's saying management needed to present more clarity

You may also be interested in...



India’s Sun Pharma To Pursue Taro Merger As Q4 Profits Surge On U.S. Protonix Sales

NEW DELHI - India's Sun Pharmaceutical said it is "on strong ground" to complete a merger with Taro Pharmaceutical at $10.25 a share, despite a rebuff by the Israel-based firm, as it reported higher than forecast earnings for the fourth quarter ended March 31 on strong sales of generic Protonix (pantoprazole) in the U.S

Dr Reddy’s Sees Revenue Growth Of 25 Percent This Financial Year, Improved Profitability

NEW DELHI - India's second biggest generic drug maker said it expects revenue growth of 25 percent in the financial year started April and gross margins of 50 percent led by improved cost control at its German betapharm unit and growing revenues from custom manufacturing and active pharmaceutical ingredient sales after earnings below expectations for the fourth quarter ended March

PharmAsia News Notable Notes: Kotak Initiates Coverage Of Five Indian CMO, CRO Firms

NEW DELHI - Efforts by five smaller Indian drug companies to attract contract research and manufacturing stand to benefit from multinational firms cost-cutting efforts in sourcing active pharmaceutical ingredients and increased clinical trials in the country

UsernamePublicRestriction

Register

OM013626

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel